Go to content Go to navigation
Alliance for Lupus Research
We're Making a Difference! Find out how
John Harley, MD, PhDJennifer Anolik, MD, PhDAnne Davidson, MD

Research with results:
SLEGEN

The ALR-funded International SLE Genetics (SLEGEN) Consortium research project has identified multiple genes linked to women with lupus. These findings set the stage for more studies that will eventually lead to earlier diagnosis and new treatments for this debilitating illness.

The three-year SLEGEN study was formed and supported with $2.25 million in funding from the Alliance for Lupus Research (ALR). Published in the January 20, 2008, issue of Nature Genetics, the results underscore the role of genetic variants in predisposing an individual to developing lupus disease.

Researchers studied the DNA of more than 6,700 women, including individuals with lupus, their family members and control subjects. After sifting through a massive database and scanning the entire genome for more than 317,000 single nucleotide polymorphisms (SNPs), they discovered robust evidence of an association to lupus in three genes - ITGAM, KIAA1542 and PXK - and at SNP rs10798269, a DNA unit not found within any known gene. SNPs are locations in the chromosomes where a single unit of DNA may vary from one person to another.

Nine other genes showed convincing evidence of linkage to lupus as well. In the end, the researchers presented data that identify 13 strong genetic candidates that may be linked to lupus.

What the SLEGEN study means for people with lupus:

Now that these genes have been identified, other scientists can seize upon these findings to start developing new strategies for prevention and therapy. These results represent a significant step toward the ALR mission of preventing, treating and curing lupus. Moving forward, SLEGEN updates will show how this study is driving further advancement in lupus treatment. The SLEGEN project opens the door to future lupus research funding that will help build on these groundbreaking results. Stay tuned to learn how researchers are building on SLEGEN to target specific genetic pathways for potential new treatments.

Slegen at a Glance

  • The Alliance for Lupus Research (ALR) founded the international research consortium in 2005.
  • The ALR supported the three-year study with $2.25 million in funding.
  • Researchers studied DNA from more than 6,700 women, including lupus patients, their families and unrelated controls.
  • After scanning the entire genome and 317,000 single nucleotide polymorphisms (SNPs), scientists found:
    • Four genes with robust evidence of genetic linkage to lupus
    • Nine other genes with promising evidence of linkage to the disease
    • The data are 99% accurate.
    • Study results appeared in the January 20, 2008, issue of Nature Genetics.
    • Results will spur more studies, leading to new treatment strategies.

Lupus Research and Lupus Treatment

Systemic lupus erythematosus, also known as SLE or lupus, is an enigmatic chronic autoimmune disease that attacks healthy cells and tissues all over the body. Because lupus symptoms such as skin rashes, low-grade fevers, and extreme fatigue mirror the symptoms of many other diseases, lupus is difficult to diagnose and treat. At present, lupus treatment ranges from rest, a healthy diet, and avoidance of known triggers to nonsteroidal anti-inflammatory drugs, immunosuppressants (or cytotoxic drugs), and other medications to control specific symptoms. However, like many an autoimmune disease, there is no cure for lupus--yet.

The Alliance for Lupus Research (ALR), a New York-based national voluntary health organization, is working to prevent, treat, and cure lupus through proactive fundraising and medical research. ALR initiatives include several research grant programs, the SLEGEN program which launched an accelerated search for the genes that put people at risk for developing lupus, advocacy for increased federal funding for lupus research, and a grassroots fundraising program called Walk with Us to Cure Lupus. To date, the ALR, now the world's largest source of private funding for lupus research, has allocated more than $55 million to programs studying lupus disease. The ALR's hope is that with continued research, lupus face rash, kidney problems, blood system disorders, and the other manifestations of this debilitating, poorly understood disease will become manageable, curable and even preventable.

This site provides further information about lupus, the ALR and its research programs, the Walk with Us to Cure Lupus event, and other events. If you would like to join the quest to cure lupus, you can also make a contribution online. Thank you for visiting the ALR!

Resources